Europäischer Rechnungshof - European Court of Auditors
Läkemedelsbristen är fortfarande en kronisk huvudvärk för EU
more
Stories about Krankheit
Europäischer Rechnungshof - European Court of Auditors
(Presskonferens) Kan EU bota bristen på kritiska läkemedel?
Kan EU bota bristen på kritiska läkemedel? - Presskonferens online onsdagen den 17 september kl. 10.00 CEST. - Offentliggörande samma dag kl. 17.00 CEST. Europeiska revisionsrätten inbjuder härmed till en presskonferens online inför offentliggörandet av en särskild rapport om EU:s åtgärder för att säkerställa ...
moreEuropäischer Rechnungshof - European Court of Auditors
(Ενημέρωση Τύπου) Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας;
Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας; - Διαδικτυακή ενημέρωση Τύπου: Τετάρτη 17 Σεπτεμβρίου, ...
moreEuropäischer Rechnungshof - European Court of Auditors
(Tiedotustilaisuus) Voiko EU löytää parannuskeinon lääkepulaan?
Voiko EU löytää parannuskeinon lääkepulaan? - Tiedotustilaisuus verkossa keskiviikkona 17. syyskuuta klo 10.00 Keski-Euroopan kesäaikaa - Kertomus julkaistaan samana päivänä klo 17.00 Keski-Euroopan kesäaikaa Euroopan tilintarkastustuomioistuin kutsuu teidät ...
moreServier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
moreTechnische Universität München
Slime as a material for multifunctional spheres
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Hollow microparticles for cargo molecules Slime as a material for multifunctional spheres - Hollow microspheres for molecular cargoes combine multiple functions - They adhere effectively to soft tissue and cartilage - Potential future applications in osteoarthritis or for oral ulcers Researchers at the Technical University of Munich (TUM) have developed hollow microspheres made ...
more
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
morePress release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
One documentmore- 2
New Endoscopy Technology Enables Early Detection of Esophageal Cancer
more Technische Universität München
A new biotech hub for Munich
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE A new biotech hub for Munich Where science powers start-ups: Launching BioLabs|TUM • TUM Venture Labs cooperate with BioLabs and Lilly • 1,800 square meters of coworking lab space • Aiming at accelerating therapy development BioLabs, TUM Venture Labs, and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups ...
moreTherapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients
moreTherVacB: Advance Curative Strategy for Chronic Hepatitis B
more
Cancer Cachexia: Liver Identified as Driver of Body Wasting
Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, affects around half of all cancer patients. It is a major cause of therapy resistance, complications, and increased mortality. ...
moreWorld Health Summit 2025: Registration Open - First High-Level Speakers Announced
Berlin (ots) - Registration for the World Health Summit 2025 is now open. From October 12-14, Berlin will once again host one of the most important strategic global health gatherings worldwide. Under the theme "Taking Responsibility for Health in a Fragmenting World", the summit brings together leading minds from academia, politics, the private sector, and civil ...
more- 2
New Label-Free Imaging Tracks Cancer Treatment in Single Cells
more Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
moreAxolt Launches Brain Supplement to Combat Post-Pandemic Burnout Crisis
moreHagleitner Hygiene International GmbH
Global Hygiene Expert Pittet: Hand Hygiene Saves 5 to 8 Million Lives Each Year
more
Less than 30 days left to apply – don’t miss your chance
One documentmoreMedHub-AI and Terumo partner to market AI-based FFR in Japan
Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...
moreInnovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250
Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...
moreBIAL Announces Oral Presentation at GBA1 Meeting 2025
Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...
moreGrünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
moreAI Meets Game Theory: How Language Models Perform in Human-Like Social Scenarios
more
NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response
Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...
moreTechnische Universität München
Identifying pathogens within minutes instead of days
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Mass spectrometry detects bacteria without time-consuming isolation and multiplication Identifying pathogens within minutes instead of days - Identification directly in tissue and stool samples - So far 232 medically important bacterial species detectable - Database must now be further expanded Speed and reliability are crucial in the diagnosis of diseases. Researchers at the ...
moreEuropäischer Rechnungshof - European Court of Auditors
(Viimeinen muistutus) EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset (Tiedotustilaisuus, 6. toukokuuta)
Kutsu tiedotustilaisuuteen 6. toukokuuta 2025 EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset - Tiedotustilaisuus verkossa tiistaina 6. toukokuuta klo 10.00 ...
moreEuropäischer Rechnungshof - European Court of Auditors
(Kutsu tiedotustilaisuuteen) EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset
Kutsu tiedotustilaisuuteen 6. toukokuuta 2025 EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset - Tiedotustilaisuus verkossa tiistaina 6. toukokuuta klo 10.00 ...
moreAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
moreHelmholtz Launches Task Force to Strengthen Prevention Research
more
12345678910Next